Carnot Curie Cancer

Curie Cancer is built on the expertise of Institut Curie (3200 people), a leading comprehensive cancer center in Europe and a world-renowned hospital.

Curie Cancer offers to industrial partners the ability to setup research collaborations from  early discovery (cognitive research) to the most advanced research stages (clinical research).

Competences

Core business

Health
Technologies for health

Hight competences

Chemistry
Key figures
Fermer

Key figures

Permanent staff (full-time equivalent)
891
including PhD Students
179
Global budget
104,9 M€
Partnership
incomes with industry
12,7 M€
Contact
Fermer

Contact

Institut Curie
Technology Transfer & Industrial Partnerships
26 rue d'Ulm
75248 Paris cedex 5
France

Amaury Martin
+33 (0)1 56 24 55 80

Géraldine Gubitta-Wane
+33 (0)1 56 24 55 84
 

Email contact
Parent institutions

Presentation

From therapeutic target… to clinical validation

   
  © Noak / Le Bar Floréal / Institut Curie  

The model of Marie Curie

  • Marie Curie, founder of Institut Curie, was attached to the seamless continuity from fundamental and clinical research to patient care. Curie Cancer maintains these dynamics and puts together leading teams in cognitive, translational and clinical research.
  • Curie Cancer offers tailor-made collaborative research projects to industrial partners, based on the internal expertise of its teams as well as the capabilities of its advanced technical platforms.
  • Curie Cancer is led by professionals with extensive experience in the pharmaceutical industry and/or biotechnology sector and thus sets up efficient collaborations with its industrial partners.

Examples of collaborative projects with industrial partners

  • Identification and validation of therapeutic targets.
  • Evaluation of drug efficiency and antitumor activity on human xenograft mice.
  • Identification of biomarkers.
  • Identification of the mechanism of drug activity in developmental medicinal chemistry.
  • Design of monoclonal antibodies against therapeutic targets.
  • Pharmacokinetic clinical studies in phase I, II or III in several types of cancer.

Target markets

  • Health
  • Cosmetics

Expertise and know-how

  • Cell and Molecular Biology
  • Immunology
  • Epigenetics
  • Radiobiology
  • Microfluidics
  • Bioinformatics
  • Biophysics
  • Medicinal chemistry
  • Imaging
  • Clinical Trials
  • Radiotherapy

      
   © Noak / Le Bar Floréal / Institut Curie / © Arnaud Echard / CNRS / Institut Curie

Technological platforms

  • Bank of tumor tissus
  • Xenografts in nude mice
  • Transgenic mice, zebra-fish, …
  • High-throughput sequencing
  • High-throughput phenotypic screening
  • Cyclotron to produce radioisotope with ultra-short half-life
  • Imaging, bioinformatics, omics